Back to Search
HASSANE ZAROUR, MD
MD
Specialist
NPI: 1710953989IndividualAccepts Medicare
Education
OTHER
Class of 1991
Research & Publications (20)
Melanoma vaccines: early progress and future promises.
PMID 12773015·Semin Cutan Med Surg·2003
6-review
NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
PMID 11782380·Cancer Res·2002
8-other
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
PMID 10987311·Cancer Res·2000
8-other
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
PMID 10618430·Proc Natl Acad Sci U S A·2000
8-other
Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
PMID 19536884·Cancer·2009
3-trial
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
PMID 19380770·J Immunol·2009
8-other
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
PMID 18779741·J Immunother·2008
3-trial
Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients.
PMID 18025241·J Immunol·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Request Appointment
This provider isn't set up for online booking yet. Once you submit, we'll reach out to their office to arrange secure delivery of your request.
Contact & Hours
- Address
- 5115 CENTRE AVE
PITTSBURGH, PA 15232 - Phone
- (412) 692-4724
Quick Facts
- NPI
- 1710953989
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 35
- Publications
- 20
Are you this provider?
Claim Your Profile